Publications by authors named "Eva Fouka"
Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice questions, concerning its efficacy and safety and its association with other asthma-related and drug-related parameters. Evidence suggests that omalizumab improves asthma control and reduces the incidence and frequency of exacerbations in patients with severe allergic asthma.
View Article and Find Full Text PDFArticle Synopsis
- Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease with an unpredictable progression, and this study aimed to assess the prognostic value of complete blood count parameters in patients diagnosed with IPF.
- The research involved analyzing data from 489 treatment-naïve IPF patients across two cohorts, focusing on monocyte count and red cell distribution width (RDW) to categorize them into high and low groups.
- Results showed that higher monocyte counts and RDW were linked to significantly poorer lung function and higher mortality rates, with similar findings confirmed in a validation cohort.
Introduction: Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed 1 year of therapy with mepolizumab.
Methods: This study is a prospective multicenter, noninterventional 2-year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma.